Parabilis Medicines initiates dose — ranging zolucatetide study in familial adenomatous polyposis

Parabilis Medicines launched a dose-ranging cohort in its Phase 1/2 trial testing zolucatetide in adults with familial adenomatous polyposis. Early proof-of-concept results were already presented from two FAP patients with desmoid tumors, showing meaningful reductions in duodenal polyp burden. The new cohort targets dose and schedule selection to support a future registrational development path in FAP. Additional results are expected in Q1 2027 from enrolled FAP patients with concomitant desmoid tumors. Zolucatetide remains in evaluation across other Wnt/β-catenin-driven tumors, with desmoid tumors, ACP, and HCC among focus areas. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parabilis Medicines Inc. published the original content used to generate this news brief via (Ref. ID: 202610140700PRIMZONEFULLFEED9845259) on October 14, 2026, and is solely responsible for the information contained therein. (C)